Status | Study |
Active, not recruiting |
Study Name: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Condition: Gastroenteropancreatic Neuroendocrine Tumors Date: 2014-09-02 Interventions: Drug: Lanreotide Autogel 120 mg |
Completed |
Study Name: 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Condition: Gastroenteropancreatic Neuroendocrine Tumors Date: 2014-06-03 Interventions: Drug: 68Ga-OPS202 |
Enrolling by invitation |
Study Name: Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Condition: This Study Plans to Include 600 GEP-NET Patients. Date: 2014-02-27 |
Terminated |
Study Name: Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors Condition: Gastroenteropancreatic Neuroendocrine Tumors Date: 2014-02-26 Interventions: Drug: Gallium-68-DOTATATE PET/CT (index test) |
Recruiting |
Study Name: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor Condition: Gastroenteropancreatic Neuroendocrine Tumor Date: 2013-11-19 Interventions: Drug: Famitinib Famitinib 25 mg p.o. qd |
Recruiting |
Study Name: 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs Condition: Gastroenteropancreatic Neuroendocrine Tumors Date: 2013-04-25 Interventions: Drug: Intravenous injection of 177Lu-octreotate Treatment will consist of 177Lu-octreotate injections in |
Completed |
Study Name: TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors Condition: Patients With Gastroenteropancreatic Neuroendocrine Tumors Date: 2012-11-13 Interventions: Drug: 68-Ga-DOTANOC |
Active, not recruiting |
Study Name: The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases Condition: Gastro-enteropancreatic Neuroendocrine Tumor Secondary Malignan Date: 2011-08-24 Interventions: Other: magnetic resonance imaging (MRI) Each patient will |
Completed |
Study Name: Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs Condition: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System Date: 2010-12-16 Interventions: Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus |